Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)
NCT02320474
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
26
Enrollment
OTHER
Sponsor class
Conditions
Type 3 Choroidal Neovascularization
Interventions
DRUG:
Aflibercept
Sponsor
Poitiers University Hospital